EGFR and non-small cell lung carcinoma: Although, some subgroups of NSCLC patients are more likely harboring mutations such as Asian females, never-smokers, with ADC, and Caucasian non-smokers (Zhang et al., 2016), the EGFR mutation testing is recommended by different organizations’ guidelines (CAP, AMP, IASLC, and ESMO) for all patients with advanced nonsquamous NSCLC regardless of clinical characteristics, including some patients with SqCC such as non-smokers or youngers (Pennell et al., 2019).